The following is a summary of the “Correlations between serum levels of microRNA-148a-3p and microRNA-485-5p and the progression and recurrence of prostate cancer” published in the November 2022 issue of Urology by He et al.


Unexpected recurrence after surgery of prostate cancer, which is one of the most common types of cancer in men around the world, has become a major problem for patients who have been treated. Here, researchers looked at the relationship between the levels of miR-148a-3p and miR-485-5p expression in the blood of PCa patients and the return of cancer. Investigators did this to find new biomarkers for diagnosing and predicting the return of prostate cancer after surgery. The study looked at 198 male PCa patients who were treated with surgery, radiotherapy after surgery, and chemotherapy. Serum levels of miR-148a-3p and miR-485-5p were measured before the first operation in the cases involved. The cases were then watched for 2 years to see if cancer came back and to divide them into groups with and without recurrence.

The relative expressions of serum miR-148a-3p and miR-485-5p were compared, and they were linked to other signs of disease in the clinic. Before surgery, the levels of miR-148a-3p in the blood of men with TNM stage cT1-2a prostate cancer (Gleason score<7) were significantly lower (P<0.05) than in men with TNM stage cT2b and higher prostate cancer (Gleason score ≥7). pre-surgery serum levels of miR-485-5p in patients with TNM stage cT1-2a prostate cancer (Gleason score <7) were significantly higher (P<0.05) than in patients with TNM stage cT2b and higher cancer (Gleason score ≥7). The recurrence group has a higher level of serum miR-148a-3p than the non-recurrence group (P<0.05), while the recurrence group has a lower level of serum miR-485-5p than the non-recurrence group (P<0.05).

The AUCs for using miR-148a-3p, miR-485-5p, and both together to predict prostate cancer recurrence were 0.825 (95% CI, 0.765–0.875, P<0.0001), 0.790 (95% CI, 0.726–0.844, P<0.0001), and 0.913 (95% CI, 0.865–0.948, P<0.0001), respectively. Levels of miR-148a-3p and miR-485-5p in the blood before surgery are linked to the progression and recurrence of prostate cancer after surgery. Both molecules have the potential to be used alone or together to predict recurrence after surgery.

Source: bmcurol.biomedcentral.com/articles/10.1186/s12894-022-01143-z